News | March 21, 2026
Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Full approval will depend on verification of clinical benefit in a confirmatory trial
The FDA aims to make a decision by April 8, 2026
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated
